touchPANEL DISCUSSION for touchHAEMATOLOGY and touchONCOLOGY
Listen to leading experts discuss guideline-directed strategies for mutational analysis and monitoring response when treating patients with chronic-phase chronic myeloid leukaemia with approved tyrosine kinase inhibitors.
Dr Jorge Cortes, Georgia Cancer Center, Augusta, GA, USADr Elias Jabbour, MD Anderson Cancer Center, Houston, TX, USA Dr Vivian Oehler, Fred Hutch Cancer Center, Seattle, WA, USAThis touchPODCAST is for HCPs in the USA only.
This activity is funded by an independent medical education grant from Takeda Development Center Americas, Inc.
Jointly provided by Partners for Advancing Clinical Education and touchIME.
For further information, visit our websites:
www.touchHAEMATOLOGY.com